Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21656854 | 1.00 | ALDH1A1 (0.63) | ALDH1A1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL21656494 | 0.99 | MAPT (0.61) | ALDH1A1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL21656498 | 0.96 | MAPT (0.57) | ALDH1A1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL21656823 | 0.93 | MAPT (0.53) | ALDH1A1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL1789154 | 0.93 | ALDH1A1 (0.63) | ALDH1A1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL21757021 | 0.86 | ALDH1A1 (0.48) | ALDH1A1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL19357414 | 0.85 | PDE4B (0.53) | ALDH1A1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL21656829 | 0.85 | PDE4B (0.53) | ALDH1A1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL21753148 | 0.85 | FDFT1 (0.52) | ALDH1A1MAPTSMN1; SMN2RAB9ACA12 | |
| SCHEMBL4003420 | 0.85 | CA12 (0.59) | ALDH1A1MAPTSMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346549-A2 | NOVEL AROMATIC MOLECULES | Xeniopro GmbH (DE) | 2025-11-13 | — | — | US | disclosed |
| EP-3429576-B1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-20250084023-A2 | NOVEL AROMATIC MOLECULES | Xeniopro GmbH (DE) | 2025-03-13 | — | — | US | disclosed |
| US-20240140895-A1 | NOVEL AROMATIC MOLECULES | Xeniopro GmbH (DE) | 2024-05-02 | — | — | US | disclosed |
| CN-112955439-A | Aromatic molecules for the treatment of pathological conditions | 赛尼欧普罗有限责任公司 | 2021-06-11 | — | — | CN | disclosed |
| US-20200360355-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2020-11-19 | — | — | US | disclosed |
| US-20200360355-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2020-11-19 | — | — | US | disclosed |
| US-10772876-B2 | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch | Xeniopro GmbH (DE) | 2020-09-15 | — | — | US | disclosed |
| US-10772876-B2 | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch | Xeniopro GmbH (DE) | 2020-09-15 | — | — | US | disclosed |
| US-20190083476-A1 | ENHANCERS OF NOTCH SIGNALING AND THE USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2019-03-21 | — | — | US | disclosed |
| US-20190083476-A1 | ENHANCERS OF NOTCH SIGNALING AND THE USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2019-03-21 | — | — | US | disclosed |
| EP-3429576-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Xeniopro GmbH (DE) | 2019-01-23 | — | — | EP | disclosed |
| WO-2017158190-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Ecole polytechnique fédérale de Lausanne (EPFL) (CH) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017158190-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | Ecole polytechnique fédérale de Lausanne (EPFL) (CH) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10772876-B2 | Enhancers of Notch signaling and the use thereof in the treatment of cancers and malignancies medicable by upregulation of Notch | NOTCH1, DNER, NOTCH4 | ALDH1A1 4100/4885MAPT 1500/4885SMN1; SMN2 495/4885 |
| US-20200360355-A1 | ENHANCERS OF NOTCH SIGNALING AND THEIR USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | NOTCH1, DNER, NOTCH4 | ALDH1A1 4068/4885MAPT 1637/4885SMN1; SMN2 541/4885 |
| US-20250084023-A2 | NOVEL AROMATIC MOLECULES | AHR, TYR, MUSK | ALDH1A1 810/4885MAPT 2300/4885SMN1; SMN2 1224/4885 |
| US-20190083476-A1 | ENHANCERS OF NOTCH SIGNALING AND THE USE THEREOF IN THE TREATMENT OF CANCERS AND MALIGNANCIES MEDICABLE BY UPREGULATION OF NOTCH | NOTCH1, DNER, NOTCH4 | ALDH1A1 4100/4885MAPT 1500/4885SMN1; SMN2 495/4885 |
| US-20250346549-A2 | NOVEL AROMATIC MOLECULES | AHR, TYR, MUSK | ALDH1A1 810/4885MAPT 2300/4885SMN1; SMN2 1224/4885 |
| US-20240140895-A1 | NOVEL AROMATIC MOLECULES | AHR, TYR, MUSK | ALDH1A1 810/4885MAPT 2300/4885SMN1; SMN2 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.